Browse Biomarkers Based on Biomarker Basis

This page shows data for Concentration Based biomarker basis.
Total Entries Retrieved: 137
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
598 Engrailed-2 (EN2) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Controls p<0.0001 Urine 21364037
808 Prostate Helth Index (phi) Protein Humans Upregulated in Gleason Score ≥7 Prognostic Gleason Score ≥7 and Gleason Score <7 p<0.0001 Blood 22078333
810 Prostate Helth Index (phi) Protein Humans Upregulated with GS upgrading Prognostic Gleason sum upgrading from 6 to 7 p<0.0001 Blood 22078333
812 Prostate Helth Index (phi) Protein Humans Upregulated in Tumor Stage pt3 Prognostic pathological stage pt2 Vs pathological stage pt3 p<0.0001 Blood 22078333
909 Prostate Health Index (phi) Protein Humans Upreregulated in PCa Diagnostic PCa VS No PCa group; PCa Vs HGPIN group p< 0.001 Serum 22542564
964 Soluble interleukin-6 Receptor (sIL-6R) Protein Humans Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 65.62±23.87 Vs With Gleason Score Upgrading: 94.63±33.31) Prognostic Gleason Score Upgrading Vs No Gleason Score Uprading p=0.024 Serum 22866141
965 Soluble interleukin-6 Receptor / Interleukin-6 ((sIL-6R/IL-6) Protein Humans Upregulated in higher Gleason Score (Without Gleason Score Upgrading: 9.23±5.78 Vs With Gleason Score Upgrading: 15.61±4.94) Prognostic Gleason Score Upgrading Vs No Gleason Score Uprading p=0.011 Serum 22866141
1027 Carbonic Anhydrase I Protein Humans Upregulated in PCa Diagnostic PCA Vs Healthy Controls p = 0.022 Plasma 23213568
1028 PSA + Carbonic Anhydrase I Protein Humans Upregulated in PCa Diagnostic PCA Vs Healthy Controls p = 0.022 Plasma 23213568
1046 Hemoglobin Others Humans NA Diagnostic PC (all stages) vs. non-cancerous conditions p < 0.05 Blood 23356551
1047 Prostate Specific Antigen (PSA) Protein Humans NA Diagnostic PC (all stages) vs. non-cancerous conditions p < 0.05 Serum 23356551
1048 blood urea nitrogen (BUN) Others Humans NA Diagnostic PC (all stages) vs. non-cancerous conditions p < 0.05 Blood 23356551
1049 Prostate biopsy clinical decision rule (PBCDR): (HGB+ Age+ PSA+ RBC+Hematuria+ Creatinine+ Black (Ethnicity) + Albumin+ MCV) Others Humans NA Diagnostic PC (all stages) vs. non-cancerous conditions p < 0.05 Tissue 23356551
1050 Prostate biopsy clinical decision rule (PBCDR): (HGB+ RBC+ Creatinine+ PSA+ Age+ MCV+ Black (ethnicity)) Others Humans NA Diagnostic PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis) p < 0.05 Tissue 23356551
1051 Hemoglobin Others Humans NA Diagnostic PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis) p < 0.001 Blood 23356551
1052 Hematuria Others Humans NA Diagnostic PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis) p < 0.05 Blood 23356551
1053 RBC Others Humans NA Diagnostic PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis) p < 0.05 Blood 23356551
1054 Prostate Specific Antigen (PSA) Protein Humans NA Diagnostic PC (stage II, III, IV) vs. other (PC stage I, PIN, BPH, prostatitis) p < 0.001 Serum 23356551
1103 Apolipoprotein B Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.01 Serum 23582881
1104 Biotinidase Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.041 Serum 23582881
1105 Cell adhesion molecule 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.046 Serum 23582881
1106 Complement factor H Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p= 0.025 Serum 23582881
1107 Ceruloplasmin Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.041 Serum 23582881
1108 Carboxypeptidase M Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.001 Serum 23582881
1109 Intercellular adhesion molecule 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.041 Serum 23582881
1110 Galectin-3-binding protein Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.009 Serum 23582881
1111 Serum paraoxonase/arylesterase 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.011 Serum 23582881
1112 Poliovirus receptor-related protein 1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.046 Serum 23582881
1113 Thrombospondin-1 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.022 Serum 23582881
1114 Transmembrane 9 superfamily member 3 Protein Humans Upregulated in Progression Free Survival Prognostic Progression Free Survival (PFS) at 12 weeks p = 0.037 Serum 23582881
1121 Asporin; Cartilage oligomeric matrix Protein (COMP); Versican; EMILIN 3; Protein Humans Upregulated in Agressive Prostate Cancer (Fold Change); [Asporin (2.14 fold); Cartilage oligomeric matrix Protein (COMP) (100 fold) ; Versican (100 fold) ; EMILIN 3 ( 6 fold); Prognostic Agressive Vs Non Agressive Prostate Cancer Asporin (p=0.00016) ; Cartilage oligomeric matrix Protein (COMP) (p = 0.00228) ; Versican ( 0.03367) ; EMILIN 3 (0.04983); Tissue 23716368
1122 Acid ceramidase Protein Humans Downregulated in Agressive Prostate Cancer 0.18 Fold Prognostic Agressive Vs Non Agressive Prostate Cancer p = 0.04983 Tissue 23716368
1124 β-CTX (β-isomer of carboxiterminal telopeptide of collagen I) Protein Humans NA Predictive Survival Vs No Survival after treatment with zoledronic acid p = 0.0049 Serum 23722472
1125 P1NP (aminoterminal propeptide of procollagen I) Protein Humans NA Predictive Survival Vs No Survival after treatment with zoledronic acid p = 0.0139 Serum 23722472
1127 Aminoadipic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1128 Cerebronic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1129 Gluconic acid Metabolites Humans Downregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1130 Glycerophosphoethanol-amine Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1131 2-Hydroxybehenic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1132 Isopentenyl pyrophosphate Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1133 Maltotriose Metabolites Humans Downregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1134 7-Methylguanine Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1135 Tricosanoic acid Metabolites Humans Upregulated in Prostate Cancer Diagnostic Malignant Vs Non Malignant p<0.0001 Tissue 23737455
1136 Aminoadipic acid Metabolites Humans Increased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.031 Tissue 23737455
1137 Gluconic acid Metabolites Humans Decreased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.036 Tissue 23737455
1138 Maltotriose Metabolites Humans Decreased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.006 Tissue 23737455
1139 Aminoadipic acid Metabolites Humans Increased in Patients with Recurrence Prognostic Recurrence Free Survival Vs No Recurrence Free Survival p =0.048 Tissue 23737455
1148 C-Reactive Protein (CRP) Protein Humans Higher levels associated with shorter biochemical failure-free survival (Both for patients with Post- radical Prostatectomy and Definitive Radiotherapy) Prognostic Biochemical Failure Free survival p = 0.009 Serum 23818401
1150 1,5-anhydroglucitol; 10-heptaadecenoate (17:1n7); 10-nonadecenoate (19:1n9); ; 15-HETE; 1-arachidonoylglycerophosphoethanolamine; 1- arachidonoylglycerophosphoinositol; 1-arachidoylglycerophosphocholine; 1-eicosadienoylglycerophosphocholine; 1-heptadecanoylglycerophosphocholine; 1-heptadecanoylglycerophosphoethanolamine; 1-linoleoylglycerophosphocholine; 1-linoleoylglycerophosphoethanolamine; 1-myristoylglycerophosphocholine; 1-oleoylglycerol; 1-oleoylglycerophosphocholine; 1-oleoylglycerophosphoethanolamine; 1-oleoylglycerophosphoinositol; 1-oleoylglycerophosphoserine; 1-palmitoleoylglycerophosphocholine; 1-palmitoleoylglycerophosphoethanolamine; 1-palmitoylglycerol; 1-palmitoylglycerophosphocholine; 1-palmitoylglycerophosphoethanolamine 1-palmitoylglycerophosphoinositol; 1-palmitoylplasmenylethanolamine; 1-stearoylglycerol; 1-stearoylglycerophosphocholine; 1-stearoylglycerophosphoethanolamine; 1-stearoylglycerophosphoglycerol; 1-stearoylglycerophosphoinositol; 2-aminoadipate; 2-aminobutyrate; 2-arachidonoylglycerophosphocholine; 2-arachidonoylglycerophosphoethanolamine; 2-docosahexaenoylglycerophosphoethanolamine; 2-hydroxybutyrate; 2-hydroxyglutarate; 2-hydroxypalmitate; 2-hydroxystearate; 2-linoleoylglycerophosphocholine; 2-linoleoylglycerophosphoethanolamine; 2-methylbutyrylcarnitine; 2-oleoylglycerophosphocholine; 2-oleoylglycerophosphoethanolamine; 2-oleoylglycerophosphoserine; 2-palmitoylglycerophosphocholine; 2-palmitoylglycerophosphoethanolamine; 2-stearoylglycerophosphocholine; 3-(4-hydroxyphenyl)lactate; 3-aminoisobutyrate; 3-carboxy-4-methyl-5-propyl-2-furanpropanoate; 3-dehydrocarnitine; 3-dephosphocoenzyme-A; 3-hydroxybutyrate; 3-hydroxyhippurate; 3-indoxyl-sulfate; 3-phosphoglycerate; 4-acetamidobutanoate; 4-androsten-3beta_17beta-diol-disulfate-1; 4-hydroxybutyrate; 4-hydroxyhippurate; 4-methyl-2-oxopentanoate; 5,6-dihydrouracil; 5-alpha-androstan-3beta_17beta-diol-disulfate 5-methylthioadenosine; 5-oxoproline; 6-sialyllactose; 6-sialyl-N-acetyllactosamine; 7-alpha-hydroxy-3-oxo-4-cholestenoate; acetylcarnitine; acetylcholine; Ac-Ser-Asp-Lys-Pro; adenine; adenosine; adenosine 5'-diphosphate; adenosine 5'-monophosphate; adenosine 5'-diphosphoribose; adenosine 5-triphosphate; adenylosuccinate; adrenate (22:4n6); agmatine; alanine; alanylleucine; alanylphenylalanine; alanyltyrosine; alpha-glutamylvaline; alpha-hydroxyisovalerate; alpha-tocopherol; androsterone sulfate; arabitol; arabonate; arachidonate (20:4n6); arginine; ascorbate; asparagine; aspartate; aspartylleucine; aspartylphenylalanine; beta-alanine; beta-hydroxyisovalerate; betaine; butyrylcarnitine; caffeine; caproate (6:0); caprylate (8:0); carnitine; catechol-sulfate; C-glycosyltryptophan; chiro-inositol; cholesterol; choline; choline phosphate; cis-aconitate; cis-vaccenate (18:1n7); citrate; citrulline; coenzyme-A; creatine; creatinine; cysteine; cysteine-glutathione-disulfide; cysteinylglycine; cystine; cytidine; cytidine 5'-diphosphocholine; cytidine 5'-monophosphate; dehydroisoandrosterone sulfate; deoxycarnitine; dihomo-linoleate (20:2n6); docosadienoate (22:2n6); docosahexaenoate (22:6n3); docosapentaenoate (22:5n3); docosapentaenoate (22:5n6); docosatrienoate (22:3n3); eicosapentaenoate (20:5n3); ergothioneine; erythritol; erythronate; ethanolamine; flavin adenine dinucleotide; fructose; fucose; fumarate; galactose; gamma-aminobutyrate; gamma-glutamylalanine; gamma-glutamylglutamate; gamma-glutamylglutamine; gamma-glutamylleucine; gamma-tocopherol; gluconate; glucose; glucose 6-phosphate; glucose 1-phosphate; glutamate; glutamate, gamma-methyl ester; glutamine; glutarate; glutarylcarnitine; glutathione, oxidized; glutathione, reduced; glycerate; glycerol; glycerol 2-phosphate; glycerol 3-phosphate; glycerophosphoethanolamine; glycerophosphorylcholine; glycine; glycochenodeoxycholate; glycylisoleucine; glycylleucine; glycylproline; glycyltyrosine; glycylvaline; guanine; guanosine; guanosine-5-monophosphate; hexanoylcarnitine; hippurate; histamine; histidine; hydroxyisovaleroyl-carnitine; hypotaurine; hypoxanthine; inosine; inositol-1-phosphate; Isobar: 15-methylpalmitate, 2-methylpalmitate; Isobar: alpha-linolenate, gamma-linolenate (18:3n3 18:3n6); Isobar: dihomo-linolenate (20:3n3, 20:3n6); Isobar: dimethylarginine (ADMA, SDMA); Isobar: eicosenoate (20:1n9, 20:1n11); Isobar: fructose-1,6-diphosphate, glucose-1,6-diphosphate, myo-inositol-1,4-diphosphate, myo-inositol-1,3-diphosphate; Isobar: 13-HODE, 9-HODE; isobutyrylcarnitine; isocitrate; isoleucine; isoleucylisoleucine; isoleucylserine; isovalerylcarnitine; kynurenine; lactate; laurate (12:0); leucine; leucylglutamate; leucylleucine; leucylphenylalanine; leucylserine; linoleate (18:2n6); lysine; malate; maltose; maltotetraose; maltotriose; mannitol; mannose; margarate (17:0); mead acid (20:3n9); methionine; methyl-alpha-glucopyranoside; methylphosphate; myo-inositol; myristate (14:0); myristoleate (14:1n5); myristoylcarnitine; N1-methylguanosine; N2-methylguanosine; N-acetylalanine; N-acetylaspartate; N-acetyl-aspartylglutamate; N-acetylgalactosamine; N-acetylglucosamine; N-acetylglutamate; N-acetylmethionine; N-acetylneuraminate; N-acetylputrescine; N-acetyltryptophan; nicotinamide; nicotinamide adenine dinucleotide, reduced; nicotinamide adenine dinucleotide; nicotinamide ribonucleotide; nicotinamide riboside; nonadecanoate (19:0); octanoylcarnitine; oleate (18:1n9); oleoylcarnitine; ophthalmate; ornithine; palmitate (16:0); palmitoleate (16:1n7); palmitoylcarnitine; palmitoyl sphingomyelin; pantothenate; p-cresol sulfate; phenol sulfate; phenylacetylglutamine; phenylalanine; phenylalanylalanine; phenylalanylaspartate; phenylalanylglutamate; phenylalanylleucine; phenyllactate; phosphate; phosphoethanolamine; pipecolate; piperine; pregnen-diol-disulfate; pro-hydroxy-pro-proline; propionylcarnitine; prostaglandin I2; pseudouridine; putrescine; pyridoxate; pyroglutamine; pyroglutamylvaline; pyruvate; quinate; ribitol; riboflavin; ribose; ribulose; S-adenosylhomocysteine; sarcosine; scyllo-inositoll; serine; serotonin; serylleucine; serylphenylalanine; S-methylcysteine; sorbitol; spermidine; spermine; sphingosine ; stearate (18:0); stearoylcarnitine; stearoyl sphingomyelin; succinate; succinylcarnitine; taurine; theobromine; threonine; threonylisoleucine; threonylleucine; threonylphenylalanine; thymol sulfate; tiglyl carnitine; trans-4-hydroxyproline; tryptophan; tryptophan betaine; tyrosine; tyrsoylleucine; uracil; urate; urea; uridine; uridine 5'-monophosphate; valerylcarnitine; valine; valylmethionine; valyltyrosine; VGAHAGEYGAEALER; xanthine; xanthosine; xylitol; xylonate; xylulose; Metabolites Humans Differentially Expressed Diagnostic Prostate Cancer Vs Controls p<0.05 Tissue 23824564
1151 Histidine; Glycine; Alanine; Kynurenine; Glutamate; Glycerol 3-phosphate (G3P); Betaine; Pipecolate 2-methylbutyrylcarnitin; Isobar: 15-methylpalmitate; 2-methylpalmitate; Threonine; Cytidine 50-diphosphocholine; Valine; Myristoleate (14:1n5); S-adenosylhomocysteine (SAH); Phosphate; Choline; 2-aminobutyrate 2-hydroxypalmitate; Glycerol; Adenine; 2-hydroxystearate; Deoxycarnitine; Fumarate; Docosadienoate (22:2n6); Metabolites Humans Increased with Upgraded Gleason Score Prognostic Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8] p<0.05 Tissue 23824564
1152 Adenosine 50 -diphosphate (ADP); Citrate; Palmitoyl-sphingomyelin; Metabolites Humans Decreased with Upgraded Gleason Score Prognostic Gleason Score Upgrading [6 to 7 (3+4) to 7(4+3) to 8] p<0.05 Tissue 23824564
1153 5,6-dihydrouracil +choline phosphate+ glycerol + methylpalmitate Metabolites Humans Differentially Expressed Prognostic Organ Confined Vs Non Orgnan Confined p<0.05 Tissue 23824564
1154 7-HOCA+ pregnen-diol disulfate +mannosyl tryptophan Metabolites Humans Differentially Expressed Prognostic Progression Free Survival (5 years) Vs No Progression Free Survival (5 years) p<0.05 Tissue 23824564
1156 Peptide ID: 3495; 3506; 3621; 3992; 4437; 4679; 4697; 5180; 6832; 7661; 8698; 9483; 9645; 10502; 11899; 12083; 13995; 14592; 15331; 18990; 19773] Protein Humans Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: [] Diagnostic Prostate Cancer and Benign Prostatic Hyperplasia Vs inflammatory and healthy prostate p< 0.0137 Plasma 23826311
1157 Peptide ID: [7098; 8863; 9673; 10706; 24050] Protein Humans Downregulated in PCa [mean(control)/mean (case)]: [Peptide ID: [7098 (3.3 fold) ; 8863 (7.7 fold) ; 9673(73.1 fold) ; 10706 (124.8 fold) ; 24050( 11.1 fold)] Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p< 0.0027 Plasma 23826311
1158 21PP + 5PP Protein Humans Differentially Expressed Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p=0.0001 Plasma 23826311
1159 Peptide ID: [1004; 2663; 5650; 7228; 9483; 9504; 10193; 10442; 10471; 10502; 17993] Protein Humans Upregulated in PCa [mean(case)/mean(control)]: Downregulated in PCa [mean(control)/mean (case)]: [] Prognostic Localised Vs Advanced Prostate Cancer p=0.0055 Plasma 23826311
1176 Prostate Health Index (phi) mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No evidence of Maligancy p <0.001 Serum 23861782
1206 Neuropeptide‐Y (NPY) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs (Normal and BPH patients) p = 0.0396 Plasma 23991666
1207 Neuropeptide‐Y (NPY) + Prostate Specific Antigen (PSA) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs (Normal and BPH patients) p = 0.0396 Plasma 23991666
1217 Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p = 0.03 Tissue 24081904
1242 iXip: [IgM] + [tPSA] Protein Humans Upregulated in PCa [PCa: 0.467 ± 0.160; Controls: 0.314 ± 0.098] Diagnostic Prostate Cancer Vs Controls p <0.001 Serum 24240583
1247 Anterior gradient 2 [AGR2] Protein Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Prostate Cancer p = 0.026 Urine 24251762
1420 Macrophage Colony Stimulating Factor (M-CSF) Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1421 CC chemokine ligand 18 (CCL-18) Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1422 Insulin-Like Growth Factor-Binding Protein 6 (IGFBP-6) Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1423 Ttumor Necrosis Factor Receptor Superfamily Member 6 (TNFRSF6) [FAS/TNFRSF6] Protein Humans Upregulated in PCa: (> 2 fold) Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia p<0.0001 Serum 24747338
1454 Prostate Health Index (phi) Protein Humans Upregulated in PCa: [Prostate Volume ≤ 35: Negative Biopsy: 41.32 (31.30–64.23), Positive Biopsy: 64.93 (23.30–252.76) 36 ≤ Prostate Volume ≤ 50 : Negative Biopsy: 35.38 (20.69–49.80), PCa: 44.56 (21.88–132.72);Prostate Volume >50: 38.34 (19.23–72.63), PCa: 46.28 (24.33–80.34)] Diagnostic Negative Vs PCa (Segregated on the basis of Prostate Volume) Prostate Volume ≤ 35:p= 0.001;36 ≤ Prostate Volume ≤ 50 : p= 0.011;Prostate Volume >50: 0.009 Serum 24978824
1455 N-terminal telopeptide of type I collagen (NTx) Protein Humans NA Prognostic Gleason Score p< 0.001 Serum 24992524
1456 N-terminal telopeptide of type I collagen (NTx) Protein Humans NA Prognostic Prostate Cancer Stage p = 0.007 Serum 24992524
1561 Linoleic Metabolites Humans Upregulated in PCa Diagnostic Prostate Cancer Vs No Cancer p=0.04 Tissue 8922296
1594 Kallikrein-related peptidase 2 [hK2]+ intact PSA+ free PSA [fPSA]+total PSA [tPSA] Protein Humans Upregulated in GS ≤ 7 Prognostic Gleason Score <7 and Gleason Score ≤7 p<0.0001 Blood 25454615
1666 tPSA Protein Humans Upregulated in PCa Cell Lines Diagnostic PCa Vs No PCa p<0.001 Serum 25847734
1676 tPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1677 fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1678 p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1679 %fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1680 %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1681 PHI Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1682 tPSA+ fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1683 tPSA+ %fPSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1684 fPSA + p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1685 %fPSA + %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1686 PSA + %fPSA + %p2PSA Protein Humans NA Prognostic High Grade PCa Vs Low Grade PCa NA Serum 25847734
1687 TIMP1 (Tissue Inhibitor Of Metalloproteinase 1) Protein Humans NA Diagnostic PCa Vs No PCa p=0.003 Serum 25967040
1688 sE-Cadherin Protein Humans NA Diagnostic PCa Vs No PCa p<0.001 Serum 25967040
1689 Clusterin Protein Humans NA Diagnostic PCa Vs No PCa p=0.004 Serum 25967040
1690 MMP9 Protein Humans Upregulated in PCa Diagnostic PCa Vs No PCa p<0.001 Serum 25967040
1691 Galectin Protein Humans Upregulated in PCa Diagnostic PCa Vs No PCa p=0.01 Serum 25967040
1692 sE-Cadherin Protein Humans Upregulated in PCa Prognostic Gleason Pattern 3 Vs 4 Vs 5 p=0.02 Serum 25967040
1693 sE-Cadherin Protein Humans Downregulated in PCa Prognostic Gleason Upgrade Vs No Gleason Upgrade p=0.03 Serum 25967040
1774 Small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00070 Blood 30352818
1775 VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00056 Blood 30352818
1776 Cholesterol esters in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00058 Blood 30352818
1777 Cholesterol esters to total lipids ratio in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00062 Blood 30352818
1778 Cholesterol esters in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00002 Blood 30352818
1779 Cholesterol esters to total lipids ratio in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00111 Blood 30352818
1780 Cholesterol esters in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00107 Blood 30352818
1781 Cholesterol esters to total lipids ratio in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00139 Blood 30352818
1782 Free cholesterol in IDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00057 Blood 30352818
1783 Free cholesterol in large LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00080 Blood 30352818
1784 Free cholesterol in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00060 Blood 30352818
1785 Free cholesterol to total lipids ratio in medium HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00055 Blood 30352818
1786 Total cholesterol in HDL3 Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00109 Blood 30352818
1787 Total cholesterol in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00095 Blood 30352818
1788 Total cholesterol to total lipids ratio in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00105 Blood 30352818
1789 Total cholesterol in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.00001 Blood 30352818
1790 Total cholesterol to total lipids ratio in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00106 Blood 30352818
1791 Total cholesterol in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00132 Blood 30352818
1792 Total cholesterol to total lipids ratio in small LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00107 Blood 30352818
1793 Total cholesterol to total lipids ratio in small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00105 Blood 30352818
1794 Phospholipids in IDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00092 Blood 30352818
1795 Phospholipids to total lipids ratio in medium LDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00046 Blood 30352818
1796 Phospholipids to total lipids ratio in medium VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.00001 Blood 30352818
1797 Phospholipids in very small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00103 Blood 30352818
1798 Phospholipids to total lipids ratio in very small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00013 Blood 30352818
1799 Total lipids in small HDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00035 Blood 30352818
1800 Triglycerides to total lipids ratio in medium VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00064 Blood 30352818
1801 Triglycerides to total lipids ratio small VLDL Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00055 Blood 30352818
1802 Ratio of omega-6 Fatty Acids to total Fatty Acids Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00080 Blood 30352818
1803 Ratio of saturated Fatty acids to total Fatty acids Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00006 Blood 30352818
1804 Isoleucine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00008 Blood 30352818
1805 Leucine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00027 Blood 30352818
1806 Tyrosine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00003 Blood 30352818
1807 Valine Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00139 Blood 30352818
1808 Albumin Metabolites Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.00065 Blood 30352818
1809 AMACR (Alpha methylacyl A coenzyme racemase) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Semen 30337219
1810 AMACR (Alpha methylacyl A coenzyme racemase) + Age Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Semen 30337219
1811 PHI (Prostate Health Index) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Serum 30926382
1812 PHID (Prostate Health Index Density) Protein Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA Serum 30926382
1882 Keratin, type II cytoskeletal 2 epidermal; Serum amyloid P‐component;Keratin, type II cytoskeletal 1; Keratin, type I cytoskeletal 9; Isoform 2 of Filamin A; Isoform 3 of Vitamin D‐binding protein; Ig kappa chain V‐II region Cum; soform 2 of Eukaryotic translation initiation 1.8 factor 2‐alpha kinase 4; Ig alpha‐1 chain C region; Afamin; Protein Humans Increased in Progression Free survival Diagnostic Prostate Cancer in African American Men Vs Normal African American Men p<0.05 Serum 30623593
1883 Complement component C8 alpha chain; Apolipoprotein A‐I; Plasminogen; Complement component C7;Isoform 2 of Inter‐alpha‐trypsin inhibitor heavy chain H4;Inter‐alpha‐trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain V‐III region BRO; Ig gamma‐2 chain C region; Ig gamma‐3 chain C region; Protein Humans Decreased in Progression Free Survival Diagnostic Prostate Cancer in African American Men Vs Normal African American Men p<0.05 Serum 30623593
1884 Complement component C8 alpha chain; Apolipoprotein A‐I; Plasminogen; Complement component C7;Isoform 2 of Inter‐alpha‐trypsin inhibitor heavy chain H4;Inter‐alpha‐trypsin inhibitor heavy chain H1; Complement C1s subcomponent; Ig heavy chain V‐III region BRO; Ig gamma‐2 chain C region; Ig gamma‐3 chain C region; Protein Humans Decreased in Overall Survival Diagnostic Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men p<0.05 Serum 30623593
1885 SCO‐spondin; Complement component C7;Isoform 2 of Ankyrin repeat and SOCS box protein 18; Gelsolin; Serum amyloid P‐component; g heavy chain V‐I region V35; Complement C1q subcomponent subunit C; Complement component C8 alpha chain; Isoform 2 of Filamin A; Inter-alpha trypsin inhibitor heavy chain H2; Protein Humans Upregulated in PCa (Keratin, type II cytoskeletal 2 epidermal (64 fold); Serum amyloid P‐component (39 fold) ;Keratin, type II cytoskeletal 1 (13 fod) ; Keratin, type I cytoskeletal 9 (12 fold) ; Isoform 2 of Filamin A (2.6 fold) ; Isoform 3 of Vitamin D‐binding protein (2.4 fold); Ig kappa chain V‐II region Cum (2.4 fold) ; Isoform 2 of Eukaryotic translation initiation 1.8 factor 2‐alpha kinase 4 (1.8 fold) ; Ig alpha‐1 chain C region (1.7 fold) ; Afamin (1.5 fold); Diagnostic Prostate Cancer in Caucasian American Men Vs Normal Caucasian American Men p<0.05 Serum 30623593
1886 Isoform 2 of Eukaryotic translation initiation factor 2‐alpha kinase 4; Keratin type I cytoskeletal 10; SCO‐ spondin; Serum amyloid P‐component; Apolipoprotein(a); Keratin, type I cytoskeletal 9; Ig kappa chain V‐IV region; Isoform 2 of Filamin A; Keratin, type II cytoskeletal 1; Keratin, type II cytoskeletal 2 epidermal; Protein Humans Downregulated in PCa [Complement component C8 alpha chain (0.07 fold); Apolipoprotein A‐I (0.04 fold); Plasminogen (0.08 fold); Complement component C7 (0.1 fold); Isoform 2 of Inter‐alpha‐trypsin inhibitor heavy chain H4 (0.2 fold); Inter‐alpha‐trypsin inhibitor heavy chain H1 (0.2 fold); Complement C1s subcomponent (0.2 fold); Ig heavy chain V‐III region BRO (0.2 fold); Ig gamma‐2 chain C region (0.2 fold); Ig gamma‐3 chain C region (0.2 fold);] Diagnostic African American men with PCa (PAA) Vs Caucasian men with PCa (PCC) p<0.05 Serum 30623593
1887 Ig heavy chain V‐III region BRO; Alpha‐1‐antitrypsin; Plasminogen (0.1‐ fold); Ig heavy chain V‐III region TIL, Hemopexin; Afamin; Inter‐alpha‐trypsin inhibitor heavy chain H1; Protein AMBP; Alpha‐1B‐glycoprotein; Complement component C8 alpha chain; Protein Humans Upregulated in PCa [Alpha‐1‐acid glycoprotein 1 (13.6‐fold); Alpha‐1B‐glycoprotein (11.6‐fold); von Willebrand factor (5.0‐fold); Ig heavy chain V‐II region NEWM (6.0‐fold); Ig heavy chain V‐III region BRO (5.7‐fold); Afamin (5.4‐fold); Apolipoprotein A‐I (4.9‐fold); Isoform 3 of Vitamin D‐binding protein (4.3‐fold); Complement C1r subcomponent (4.3‐ fold); Angiotensinogen (4.1‐fold); Diagnostic African American men with PCa (PAA) Vs Caucasian men with PCa (PCC) p<0.05 Serum 30623593
1888 4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; 1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone Metabolites Humans Downregulated in PCa [SCO‐spondin (0.1 fold); Complement component C7 (0.1‐fold); Isoform 2 of Ankyrin repeat and SOCS box protein 18 (0.3‐fold); Gelsolin (0.3‐fold); Serum amyloid P-component (0.4‐fold); Ig heavy chain V‐I region V35 (0.5‐fold); Complement C1q subcomponent subunit C (0.5‐fold); Complement component C8 alpha chain (0.6‐fold); Isoform 2 of Filamin A (0.6‐fold); and Inter-alpha-trypsin inhibitor heavy chain H2 (0.7‐fold);] Diagnostic Prostate Cancer Vs No Prostate Cancer p<0.05 Urine 30853355